|
Published: April 29, 2025
$1M awarded to research link between cardiovascular risk reduction, GLP-1 use
The American Heart Association funds seven new scientific research studies to identify predictors of cardiovascular risk reduction among people with obesity, cardiovascular disease who take GLP-1 medications
Related Images
Previous Slide
Next Slide
Tirzepatide injection
Tirzepatide is a GIP and GLP-1 receptor agonist. Prescribed uses include Type-2 diabetes, overweight/obesity and some forms of sleep apnea.
Tirzepatide injection
Tirzepatide is a GIP and GLP-1 receptor agonist. Prescribed uses include Type-2 diabetes, overweight/obesity and some forms of sleep apnea.
Please see AHA/ASA Multimedia Materials Usage Policy .
American Heart Association Precision Medicine Platform logo
copyright American Heart Association
American Heart Association logo
Heart and Torch with American Heart Association text.
https://www.heart.org/en
Usage agreement
copyright American Heart Association
This link is provided for convenience only and is not an endorsement of either the linked-to entity or any product or service.
